Carbapenem-Based Antibiotics Global Market Report 2025

Description

Carbapenem-based antibiotics represent a class of broad-spectrum antibacterial drugs known for their high efficacy against various bacterial infections. These antibiotics are particularly effective against both gram-positive and gram-negative bacteria, including strains that may be resistant to other types of antibiotics.

The primary types of carbapenem-based antibiotics include meropenem, imipenem, doripenem, tebipenem, and others. Meropenem, for instance, is a broad-spectrum antibiotic that works by inhibiting bacterial cell wall synthesis, making it effective against a wide range of bacterial infections. It is employed in the treatment of serious bacterial infections such as pneumonia, meningitis, intra-abdominal infections, urinary tract infections, and skin and soft tissue infections. Carbapenem-based antibiotics find application in treating various conditions, including intra-abdominal infections, urinary tract infections, pneumonia, bacterial meningitis, skin and skin structure infections, acute pelvic infections, prophylaxis of surgical site infection, respiratory tract infections, and gynecologic infections. These antibiotics are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The carbapenem-based antibiotics market research report is one of a series of new reports from The Business Research Company that provides carbapenem-based antibiotics market statistics, including the carbapenem-based antibiotics industry's global market size, regional shares, competitors with a carbapenem-based antibiotics market share, detailed carbapenem-based antibiotics market segments, market trends, and opportunities, and any further data you may need to thrive in the carbapenem-based antibiotics industry. This carbapenem-based antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The carbapenem-based antibiotics market size has grown steadily in recent years. It will grow from $4.6 billion in 2024 to $4.82 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to epidemics and pandemics, rise in chronic diseases, healthcare infrastructure growth, rapid urbanization, natural disasters and health emergencies

The carbapenem-based antibiotics market size is expected to see strong growth in the next few years. It will grow to $6.09 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to increased incidence of hospital-acquired infections, emergence of multi-drug resistant strains, growing aging population, rise in surgical procedures, proliferation of infectious diseases, changing demographics. Major trends in the forecast period include supply chain resilience and security, alternative treatment development, shift towards outpatient settings, growing awareness on antimicrobial stewardship, precision medicine approaches.

The rising incidence of bacterial infections is anticipated to drive the growth of the carbapenem-based antibiotics market in the future. Bacterial infections are caused by bacteria, which are microscopic organisms that can invade the body, leading to various diseases and symptoms. Carbapenem-based antibiotics are effective in treating severe or multidrug-resistant bacterial infections, including those caused by both gram-positive and gram-negative bacteria. For instance, in July 2024, a report published by the Centers for Disease Control and Prevention (CDC), a US government agency, noted that in 2023, 78% of all bacterial infections were diagnosed using culture-independent diagnostic tests (CIDTs) in the historic catchment area, with 46% diagnosed exclusively through CIDTs. Thus, the rising incidence of bacterial infections is propelling the growth of the carbapenem-based antibiotics market.

The increasing number of surgical procedures is also expected to contribute to the growth of the carbapenem-based antibiotics market in the future. Surgical procedures involve medical interventions performed by qualified surgeons to treat, repair, remove, or replace body parts affected by disease or injury. Carbapenems provide a broad spectrum of activity, effectively targeting infections in the abdominal cavity, combating infections, and reducing the necessity for combination therapy, thereby simplifying treatment regimens for surgical patients. For example, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based organization, reported that aesthetic procedures reached nearly 35 million in 2023, with the total number of surgical and non-surgical procedures increasing by 3.4% to 34.9 million. Therefore, the rising number of surgical procedures is driving the growth of the carbapenem-based antibiotics market.

Product innovations are a significant trend gaining traction in the carbapenem-based antibiotics market. Major companies in this sector are developing new products to maintain their competitive edge. For example, in August 2024, the National Health Service (NHS), a UK government department, introduced a groundbreaking subscription model for antibiotics in partnership with the pharmaceutical industry to address antimicrobial resistance (AMR). Announced on August 12, 2024, this innovative scheme allows pharmaceutical companies to receive fixed annual payments-up to £20 million per drug-regardless of the quantity prescribed, effectively eliminating incentives for overprescribing. Valued at approximately £1.9 billion over 16 years, the initiative aims to promote the development of new antibiotics by ensuring financial sustainability for drug manufacturers. Following a successful pilot phase, this initiative is part of the UK's broader strategy to combat AMR, which poses a severe global health risk that could lead to millions of deaths by 2050 if not tackled. The NHS will prioritize products targeting critical pathogens identified by the World Health Organization, reinforcing its dedication to responsible antibiotic stewardship while encouraging innovation in antibiotic development.

Leading companies in the carbapenem-based antibiotics market are concentrating on investments to drive revenue growth. For instance, in September 2024, Hikma Pharmaceuticals, a US-based pharmaceutical company, launched Clindamycin Injection in 5% Dextrose in the United States, providing a new treatment option for severe bacterial infections caused by susceptible gram-positive bacteria. Available in ready-to-use 50 mL containers with dosages of 600 mg and 900 mg, this injectable antibiotic is especially advantageous for patients with penicillin allergies. The introduction of this product expands treatment options for healthcare providers managing complex infections, such as respiratory and skin infections, while reinforcing Hikma's commitment to tackling antibiotic resistance and enhancing patient care through accessible medication solutions.

In September 2022, GSK PLC, a pharmaceutical and biotechnology company based in the UK, and Spero Therapeutics, Inc. entered into an exclusive license agreement. The agreement involved an upfront payment of $66 million, with the potential for future milestone payments and tiered royalties. This exclusive license granted GSK the commercialization rights for tebipenem HBr in all regions except for Japan and certain other Asian countries. Spero Therapeutics, a US-based clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments and medicines for bacterial infections, including multi-drug resistant and rare diseases, particularly in the realm of carbapenem oral antibiotics.

Major companies operating in the carbapenem-based antibiotics market include Pfizer Inc., Merck & Co. Inc., Fresenius Kabi LLC, GlaxoSmithKline Plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., AstraZeneca plc, Meiji Holdings Co. Ltd., Sandoz International GmbH, Sumitomo Dainippon Pharma Co. Ltd., Shionogi & Co Ltd., Aurobindo Pharma Ltd., Acurx Pharmaceuticals LLC, Daewoong Pharmaceutical Co. Ltd., CeramTec GmbH, ACS Dobfar S.p.A, JW Pharmaceutical Corp, Centrient Pharmaceuticals Co, Spero Therapeutics Inc., Kopran Limited, Savior Lifetec Corporation, Flagship Biotech International Pvt. Ltd., Iterum Therapeutics plc, Cam Carbapenem-based antibiotics BV, Intelicure Lifesciences, Ikeda Corporation

North America was the largest region in the Carbapenem-Based Antibiotics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carbapenem-based antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the carbapenem-based antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The carbapenem-based antibiotics market consists of sales of imipenem-cilastatin, meropenem, ertapenem, doripenem, biapenem, panipenem, tebipenem, razupenem, tomopenem, and faropenem. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Carbapenem-Based Antibiotics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on carbapenem-based antibiotics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for carbapenem-based antibiotics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The carbapenem-based antibiotics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Meropenem; Imipenem; Doripenem; Tebipenem; Other Types
2) By Indication: Intra-abdominal Infections; Urinary Tract Infections; Pneumonia; Bacterial Meningitis; Skin And Skin Structure Infections; Acute Pelvic Infections; Prophylaxis of Surgical Site Infection; Respiratory Tract Infections; Gynecological Infections; Other Indications
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) By Meropenem: Meropenem Injection; Meropenem and Vaborbactam Combination; Meropenem for Pediatric Use
2) By Imipenem: Imipenem and Cilastatin Combination; Imipenem and Relebactam Combination; Imipenem Monotherapy
3) By Doripenem: Doripenem Injection; Doripenem for Complicated Infections
4) By Tebipenem: Tebipenem for Oral Administration; Tebipenem Pediatric Formulations; Tebipenem for Resistant Infections
5) By Other Types: Ertapenem; Panipenem; Faropenem; Combinations with Beta-Lactamase Inhibitors
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Fresenius Kabi LLC; GlaxoSmithKline Plc; Eli Lilly and Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24773

1. Executive Summary

2. Carbapenem-Based Antibiotics Market Characteristics

3. Carbapenem-Based Antibiotics Market Trends And Strategies

4. Carbapenem-Based Antibiotics Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Carbapenem-Based Antibiotics Growth Analysis And Strategic Analysis Framework

5.1. Global Carbapenem-Based Antibiotics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Carbapenem-Based Antibiotics Market Growth Rate Analysis
5.4. Global Carbapenem-Based Antibiotics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Carbapenem-Based Antibiotics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Carbapenem-Based Antibiotics Total Addressable Market (TAM)

6. Carbapenem-Based Antibiotics Market Segmentation

6.1. Global Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Meropenem
Imipenem
Doripenem
Tebipenem
Other Types
6.2. Global Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intra-abdominal Infections
Urinary Tract Infections
Pneumonia
Bacterial Meningitis
Skin And Skin Structure Infections
Acute Pelvic Infections
Prophylaxis of Surgical Site Infection
Respiratory Tract Infections
Gynecological Infections
Other Indications
6.3. Global Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Carbapenem-Based Antibiotics Market, Sub-Segmentation Of Meropenem, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Meropenem Injection
Meropenem and Vaborbactam Combination
Meropenem for Pediatric Use
6.5. Global Carbapenem-Based Antibiotics Market, Sub-Segmentation Of Imipenem, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Imipenem and Cilastatin Combination
Imipenem and Relebactam Combination
Imipenem Monotherapy
6.6. Global Carbapenem-Based Antibiotics Market, Sub-Segmentation Of Doripenem, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Doripenem Injection
Doripenem for Complicated Infections
6.7. Global Carbapenem-Based Antibiotics Market, Sub-Segmentation Of Tebipenem, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tebipenem for Oral Administration
Tebipenem Pediatric Formulations
Tebipenem for Resistant Infections
6.8. Global Carbapenem-Based Antibiotics Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ertapenem
Panipenem
Faropenem
Combinations with Beta-Lactamase Inhibitors

7. Carbapenem-Based Antibiotics Market Regional And Country Analysis

7.1. Global Carbapenem-Based Antibiotics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Carbapenem-Based Antibiotics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Carbapenem-Based Antibiotics Market

8.1. Asia-Pacific Carbapenem-Based Antibiotics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Carbapenem-Based Antibiotics Market

9.1. China Carbapenem-Based Antibiotics Market Overview
9.2. China Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Carbapenem-Based Antibiotics Market

10.1. India Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Carbapenem-Based Antibiotics Market

11.1. Japan Carbapenem-Based Antibiotics Market Overview
11.2. Japan Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Carbapenem-Based Antibiotics Market

12.1. Australia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Carbapenem-Based Antibiotics Market

13.1. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Carbapenem-Based Antibiotics Market

14.1. South Korea Carbapenem-Based Antibiotics Market Overview
14.2. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Carbapenem-Based Antibiotics Market

15.1. Western Europe Carbapenem-Based Antibiotics Market Overview
15.2. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Carbapenem-Based Antibiotics Market

16.1. UK Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Carbapenem-Based Antibiotics Market

17.1. Germany Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Carbapenem-Based Antibiotics Market

18.1. France Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Carbapenem-Based Antibiotics Market

19.1. Italy Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Carbapenem-Based Antibiotics Market

20.1. Spain Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Carbapenem-Based Antibiotics Market

21.1. Eastern Europe Carbapenem-Based Antibiotics Market Overview
21.2. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Carbapenem-Based Antibiotics Market

22.1. Russia Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Carbapenem-Based Antibiotics Market

23.1. North America Carbapenem-Based Antibiotics Market Overview
23.2. North America Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Carbapenem-Based Antibiotics Market

24.1. USA Carbapenem-Based Antibiotics Market Overview
24.2. USA Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Carbapenem-Based Antibiotics Market

25.1. Canada Carbapenem-Based Antibiotics Market Overview
25.2. Canada Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Carbapenem-Based Antibiotics Market

26.1. South America Carbapenem-Based Antibiotics Market Overview
26.2. South America Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Carbapenem-Based Antibiotics Market

27.1. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Carbapenem-Based Antibiotics Market

28.1. Middle East Carbapenem-Based Antibiotics Market Overview
28.2. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Carbapenem-Based Antibiotics Market

29.1. Africa Carbapenem-Based Antibiotics Market Overview
29.2. Africa Carbapenem-Based Antibiotics Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Carbapenem-Based Antibiotics Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Carbapenem-Based Antibiotics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Carbapenem-Based Antibiotics Market Competitive Landscape And Company Profiles

30.1. Carbapenem-Based Antibiotics Market Competitive Landscape
30.2. Carbapenem-Based Antibiotics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Fresenius Kabi LLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. GlaxoSmithKline Plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Carbapenem-Based Antibiotics Market Other Major And Innovative Companies

31.1. Teva Pharmaceutical Industries Ltd.
31.2. AstraZeneca plc
31.3. Meiji Holdings Co. Ltd.
31.4. Sandoz International GmbH
31.5. Sumitomo Dainippon Pharma Co. Ltd.
31.6. Shionogi & Co Ltd.
31.7. Aurobindo Pharma Ltd.
31.8. Acurx Pharmaceuticals LLC
31.9. Daewoong Pharmaceutical Co. Ltd.
31.10. CeramTec GmbH
31.11. ACS Dobfar S.p.A
31.12. JW Pharmaceutical Corp
31.13. Centrient Pharmaceuticals Co
31.14. Spero Therapeutics Inc.
31.15. Kopran Limited

32. Global Carbapenem-Based Antibiotics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Carbapenem-Based Antibiotics Market

34. Recent Developments In The Carbapenem-Based Antibiotics Market

35. Carbapenem-Based Antibiotics Market High Potential Countries, Segments and Strategies

35.1 Carbapenem-Based Antibiotics Market In 2029 - Countries Offering Most New Opportunities
35.2 Carbapenem-Based Antibiotics Market In 2029 - Segments Offering Most New Opportunities
35.3 Carbapenem-Based Antibiotics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer